Lucy Scientific Discovery Inc. (LSDI) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
301-1321 BLANSHARD STREET VICTORIA, BC V8W 0B6 |
| State of Incorp. | BC |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2023 | |||
|---|---|---|---|
| ASSETS | |||
| Current Assets | |||
| Cash, cash equivalents, and short-term investments | |||
| Cash and cash equivalent | |||
| Receivables | |||
| Prepaid expense | |||
| Deferred costs | |||
| Other undisclosed current assets | |||
| Total current assets: | |||
| Noncurrent Assets | |||
| Operating lease, right-of-use asset | |||
| Property, plant and equipment | |||
| Long-term investments and receivables | |||
| Long-term investments | |||
| Intangible assets, net (including goodwill) | |||
| Intangible assets, net (excluding goodwill) | |||
| Prepaid expense | |||
| Total noncurrent assets: | |||
| TOTAL ASSETS: | |||
| LIABILITIES AND EQUITY | |||
| Liabilities | |||
| Current Liabilities | |||
| Accounts payable and accrued liabilities, including: | |||
| Accounts payable | |||
| Other undisclosed accounts payable and accrued liabilities | |||
| Debt | |||
| Other undisclosed current liabilities | |||
| Total current liabilities: | |||
| Noncurrent Liabilities | |||
| Liabilities, other than long-term debt | |||
| Operating lease, liability | |||
| Total noncurrent liabilities: | |||
| Total liabilities: | |||
| Equity | |||
| Equity, attributable to parent | |||
| Common stock | |||
| Accumulated other comprehensive income | |||
| Accumulated deficit | |||
| Total equity: | |||
| TOTAL LIABILITIES AND EQUITY: | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2023 | ||
|---|---|---|
| Revenues | ||
| Loss on disposition of assets for financial service operations | ||
| Cost of revenue | ||
| Gross profit: | ||
| Operating expenses | ||
| Operating loss: | ||
| Nonoperating expense | ||
| Interest and debt expense | ||
| Net loss: | ||
| Other undisclosed net income attributable to parent | ||
| Net loss available to common stockholders, diluted: | ||
Comprehensive Income ($ in thousands)
| 6/30/2023 | ||
|---|---|---|
| Net loss: | ||
| Comprehensive loss: | ||
| Other undisclosed comprehensive income, net of tax, attributable to parent | ||
| Comprehensive loss, net of tax, attributable to parent: | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.